GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » EV-to-EBIT
Switch to:

Biohaven (NYSE:BHVN) EV-to-EBIT

: -10.23 (As of Today)
View and export this data going back to 2022. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biohaven's Enterprise Value is $1,213.04 Mil. Biohaven's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-118.52 Mil. Therefore, Biohaven's EV-to-EBIT for today is -10.23.

The historical rank and industry rank for Biohaven's EV-to-EBIT or its related term are showing as below:

BHVN' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.97   Med: 0   Max: 0
Current: -10.34

BHVN's EV-to-EBIT is ranked worse than
100% of 513 companies
in the Biotechnology industry
Industry Median: 4.08 vs BHVN: -10.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biohaven's Enterprise Value for the quarter that ended in Sep. 2022 was $175.08 Mil. Biohaven's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-118.52 Mil. Biohaven's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -67.70%.


Biohaven EV-to-EBIT Historical Data

The historical data trend for Biohaven's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
EV-to-EBIT
- -

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
EV-to-EBIT Premium Member Only - - - - -1.48

Competitive Comparison

For the Biotechnology subindustry, Biohaven's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biohaven's EV-to-EBIT falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBIT's extreme value range as defined by GuruFocus.



Biohaven EV-to-EBIT Calculation

Biohaven's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1213.037/-118.52
=-10.23

Biohaven's current Enterprise Value is $1,213.04 Mil.
Biohaven's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-118.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven  (NYSE:BHVN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biohaven's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=-118.52/175.07738
=-67.70 %

Biohaven's Enterprise Value for the quarter that ended in Sep. 2022 was $175.08 Mil.
Biohaven's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-118.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biohaven's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership